StocksMedium•5 November 2026•
1 min read
Lantheus Welcomes CMS Final Rule Maintaining Diagnostic Radiopharmaceutical Payments
Key Facts
1CMS issued the CY27 Final Rule maintaining separate payment for advanced diagnostic radiopharmaceuticals.
2The PYLARIFY TruVu Transitional Pass-Through status was confirmed through September 30, 2029.
The Centers for Medicare & Medicaid Services (CMS) issued the CY27 Final Rule maintaining separate payment for advanced diagnostic radiopharmaceuticals. GlobeNewswire reported that the ruling confirmed the PYLARIFY TruVu Transitional Pass-Through status for Lantheus through September 30, 2029, ensuring these agents are paid for separately rather than bundled.
The rule aims to advance patient access to diagnostic imaging agents by ensuring separate reimbursement, which supports the broader adoption of precision diagnostics. LNTH closed at $101.14 on November 4, 2026, as the final rule provides the company with long-term regulatory and reimbursement certainty for its key diagnostic products.